Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 115

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 115
---
 capacities indicated below the Registration
Statement on Form F-3 filed herewith and any and all amendments (including post-effective amendments) to said Registration Statement,
and any registration statement filed pursuant to Rule 462 under the Securities Act of 1933, as amended, in connection with said Registration
Statement, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, and generally to do all such things in our name and on our behalf in our capacities as officers and
directors to enable Biodexa Pharmaceuticals PLC to comply with the provisions of the Securities Act of 1933, as amended, and all requirements
of the Securities and Exchange Commission, hereby ratifying and confirming that said attorneys, or their substitute or substitutes, shall
do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement on Form F-3 has been signed by the following persons in the capacities and on the
date indicated.

| Name and Signature        
 /s/ Stephen Stamp         |     | Title(s)                                                                                  
 Chief Executive Officer, Director,                                                        |     | Date               
 September 26, 2025 |
|:--------------------------|:----|:------------------------------------------------------------------------------------------|:----|:-------------------|
| Stephen Stamp             |     | Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer |     |                    |
| /s/ Stephen Parker        |     | Non-Executive Chairman of the Board                                                       |     | September 26, 2025 |
| Stephen Parker            |     |                                                                                           |     |                    |
| /s/ Simon Turton, Ph.D.   |     | Senior Independent Non-Executive Director                                                 |     | September 26, 2025 |
| Simon Turton, Ph.D.       |     |                                                                                           |     |                    |
| /s/ Sijmen de Vries, M.D. |     | Non-Executive Director                                                                    |     | September 26, 2025 |
| Sijmen de Vries, M.D.     |     |                                                                                           |     |                    |
| /s/ Ann Merchant          |     | Non-Executive Director                                                                    |     | September 26, 2025 |
| Ann Merchant              |     |                                                                                           |     |                    |

<div align='center'>SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE</